StreetInsider.com News Articles

RedHill's RHB-102 Progresses in Multiple GI Indications Including GLP-1 Therapy-Related GI Side Effects

Mon, 05 Jan 2026 07:00:00 -0400

RHB-102¹ is a proprietary, advanced clinical-stage, once-daily, bimodal extended-release, oral tablet formulation of 5-HT3 antagonist, ondansetron, targeting oncology support, acute gastroenteritis and gastritis, IBS-D and GLP-1/GIP-associated gastrointestinal (GI) side effects

Largey de-risked, RHB-102 development is supported by published positive U.S. Phase 3 & 2 results in gastroenteritis/gastritis and diarrhea-predominant irritable bowel syndrome (IBS-D) respectively, a positive comparative PK clinical study as part of the oncology support (CINV/RINV) program², plus decades of ondansetron clinical use (>22 million annual U.S. ER prescriptions³)

RHB-102 is clinically aligned, if approved, to improve titration success and

RedHill's RHB-102 Progresses in Multiple GI Indications Including GLP-1 Therapy-Related GI Side Effects

Mon, 05 Jan 2026 07:00:00 -0400

RHB-102¹ is a proprietary, advanced clinical-stage, once-daily, bimodal extended-release, oral tablet formulation of 5-HT3 antagonist, ondansetron, targeting oncology support, acute gastroenteritis and gastritis, IBS-D and GLP-1/GIP-associated gastrointestinal (GI) side effects
--
Largey de-risked, RHB-102 development is supported by published positive U.S. Phase 3 & 2 results in gastroenteritis/gastritis and diarrhea-predominant irritable bowel syndrome (IBS-D) respectively, a positive comparative PK clinical study as part of the oncology support (CINV/RINV) program², plus decades of ondansetron clinical use (>22 million annual U.S. ER prescriptions³)
--
RHB-102 is clinically aligned, if approved, to improve titration success and

RedHill's RHB-102 Progresses in Multiple GI Indications Including GLP-1 Therapy-Related GI Side Effects

Mon, 05 Jan 2026 07:00:00 -0400

RHB-102¹ is a proprietary, advanced clinical-stage, once-daily, bimodal extended-release, oral tablet formulation of 5-HT3 antagonist, ondansetron, targeting oncology support, acute gastroenteritis and gastritis, IBS-D and GLP-1/GIP-associated gastrointestinal (GI) side effects
--
Largey de-risked, RHB-102 development is supported by published positive U.S. Phase 3 & 2 results in gastroenteritis/gastritis and diarrhea-predominant irritable bowel syndrome (IBS-D) respectively, a positive comparative PK clinical study as part of the oncology support (CINV/RINV) program², plus decades of ondansetron clinical use (>22 million annual U.S. ER prescriptions³)
--
RHB-102 is clinically aligned, if approved, to improve titration success and

RedHill's RHB-102 Progresses in Multiple GI Indications Including GLP-1 Therapy-Related GI Side Effects

Mon, 05 Jan 2026 07:00:00 -0400

RHB-102¹ is a proprietary, advanced clinical-stage, once-daily, bimodal extended-release, oral tablet formulation of 5-HT3 antagonist, ondansetron, targeting oncology support, acute gastroenteritis and gastritis, IBS-D and GLP-1/GIP-associated gastrointestinal (GI) side effects
--
Largey de-risked, RHB-102 development is supported by published positive U.S. Phase 3 & 2 results in gastroenteritis/gastritis and diarrhea-predominant irritable bowel syndrome (IBS-D) respectively, a positive comparative PK clinical study as part of the oncology support (CINV/RINV) program², plus decades of ondansetron clinical use (>22 million annual U.S. ER prescriptions³)
--
RHB-102 is clinically aligned, if approved, to improve titration success and

RedHill's RHB-102 Progresses in Multiple GI Indications Including GLP-1 Therapy-Related GI Side Effects

Mon, 05 Jan 2026 07:00:00 -0400

RHB-102¹ is a proprietary, advanced clinical-stage, once-daily, bimodal extended-release, oral tablet formulation of 5-HT3 antagonist, ondansetron, targeting oncology support, acute gastroenteritis and gastritis, IBS-D and GLP-1/GIP-associated gastrointestinal (GI) side effects
--
Largey de-risked, RHB-102 development is supported by published positive U.S. Phase 3 & 2 results in gastroenteritis/gastritis and diarrhea-predominant irritable bowel syndrome (IBS-D) respectively, a positive comparative PK clinical study as part of the oncology support (CINV/RINV) program², plus decades of ondansetron clinical use (>22 million annual U.S. ER prescriptions³)
--
RHB-102 is clinically aligned, if approved, to improve titration success and

RedHill's RHB-102 Progresses in Multiple GI Indications Including GLP-1 Therapy-Related GI Side Effects

Mon, 05 Jan 2026 07:00:00 -0400

RHB-102¹ is a proprietary, advanced clinical-stage, once-daily, bimodal extended-release, oral tablet formulation of 5-HT3 antagonist, ondansetron, targeting oncology support, acute gastroenteritis and gastritis, IBS-D and GLP-1/GIP-associated gastrointestinal (GI) side effects
--
Largey de-risked, RHB-102 development is supported by published positive U.S. Phase 3 & 2 results in gastroenteritis/gastritis and diarrhea-predominant irritable bowel syndrome (IBS-D) respectively, a positive comparative PK clinical study as part of the oncology support (CINV/RINV) program², plus decades of ondansetron clinical use (>22 million annual U.S. ER prescriptions³)
--
RHB-102 is clinically aligned, if approved, to improve titration success and

RedHill Biopharma appeals Nasdaq delisting notice

Wed, 22 Oct 2025 16:51:08 -0400

RedHill Biopharma Ltd. (NASDAQ: RDHL) received a staff determination notification from Nasdaq on October 16 regarding continued non-compliance with minimum stockholders' equity requirements for listing.
The specialty biopharmaceutical company failed to meet the $2.5 million minimum stockholders' equity requirement by the October 13 compliance deadline, according to Nasdaq Listing Rule 5550(b)(1). Nasdaq initially notified RedHill of the non-compliance on April 17 and granted an extension until October 13.
RedHill plans to appeal the determination to a Nasdaq Listing Qualifications Panel, which has authority to determine compliance or grant up to a 180-day extension. The hearing request will stay any delisting or suspension

RedHill Biopharma appeals Nasdaq delisting notice

Wed, 22 Oct 2025 16:51:08 -0400

RedHill Biopharma Ltd. (NASDAQ: RDHL) received a staff determination notification from Nasdaq on October 16 regarding continued non-compliance with minimum stockholders' equity requirements for listing.
The specialty biopharmaceutical company failed to meet the $2.5 million minimum stockholders' equity requirement by the October 13 compliance deadline, according to Nasdaq Listing Rule 5550(b)(1). Nasdaq initially notified RedHill of the non-compliance on April 17 and granted an extension until October 13.
RedHill plans to appeal the determination to a Nasdaq Listing Qualifications Panel, which has authority to determine compliance or grant up to a 180-day extension. The hearing request will stay any delisting or suspension

RedHill Biopharma Receives Nasdaq Staff Determination Notification

Wed, 22 Oct 2025 16:50:00 -0400

On October 16, 2025, the Company received a Staff Determination notification from The Nasdaq Stock Market LLC regarding continued non-compliance with the minimum stockholders' equity requirements for continued listing, pursuant to Listing Rule 5550(b)(1)

RedHill Biopharma Receives Nasdaq Staff Determination Notification

Wed, 22 Oct 2025 16:50:00 -0400

On October 16, 2025, the Company received a Staff Determination notification from The Nasdaq Stock Market LLC regarding continued non-compliance with the minimum stockholders' equity requirements for continued listing, pursuant to Listing Rule 5550(b)(1)

RedHill Biopharma Receives Nasdaq Staff Determination Notification

Wed, 22 Oct 2025 16:50:00 -0400

On October 16, 2025, the Company received a Staff Determination notification from The Nasdaq Stock Market LLC regarding continued non-compliance with the minimum stockholders' equity requirements for continued listing, pursuant to Listing Rule 5550(b)(1)

RedHill Biopharma Receives Nasdaq Staff Determination Notification

Wed, 22 Oct 2025 16:50:00 -0400

On October 16, 2025, the Company received a Staff Determination notification from The Nasdaq Stock Market LLC regarding continued non-compliance with the minimum stockholders' equity requirements for continued listing, pursuant to Listing Rule 5550(b)(1)

RedHill Biopharma Receives Nasdaq Staff Determination Notification

Wed, 22 Oct 2025 16:50:00 -0400

On October 16, 2025, the Company received a Staff Determination notification from The Nasdaq Stock Market LLC regarding continued non-compliance with the minimum stockholders' equity requirements for continued listing, pursuant to Listing Rule 5550(b)(1)

RedHill Biopharma Receives Nasdaq Staff Determination Notification

Wed, 22 Oct 2025 16:50:00 -0400

On October 16, 2025, the Company received a Staff Determination notification from The Nasdaq Stock Market LLC regarding continued non-compliance with the minimum stockholders' equity requirements for continued listing, pursuant to Listing Rule 5550(b)(1)

Cumberland Pharmaceuticals partners with RedHill for Talicia commercialization

Mon, 20 Oct 2025 09:05:29 -0400

Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced a joint commercialization agreement with RedHill Biopharma Ltd. (NASDAQ: RDHL) for Talicia, an FDA-approved treatment for Helicobacter pylori infection in adults.
Under the agreement, the companies will form a jointly owned entity. RedHill will contribute Talicia assets, including international licenses and associated revenues, while Cumberland will provide $4 million in investment capital. Cumberland will handle distribution and record product sales, with both companies sharing net revenues equally.
Talicia generated $8 million in net revenues in 2024. The oral capsule combines omeprazole, amoxicillin and rifabutin in a single treatment and demonstrates eradication rates above 90%. The American

Cumberland Pharmaceuticals partners with RedHill for Talicia commercialization

Mon, 20 Oct 2025 09:05:29 -0400

Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced a joint commercialization agreement with RedHill Biopharma Ltd. (NASDAQ: RDHL) for Talicia, an FDA-approved treatment for Helicobacter pylori infection in adults.
Under the agreement, the companies will form a jointly owned entity. RedHill will contribute Talicia assets, including international licenses and associated revenues, while Cumberland will provide $4 million in investment capital. Cumberland will handle distribution and record product sales, with both companies sharing net revenues equally.
Talicia generated $8 million in net revenues in 2024. The oral capsule combines omeprazole, amoxicillin and rifabutin in a single treatment and demonstrates eradication rates above 90%. The American

Cumberland Pharmaceuticals partners with RedHill for Talicia commercialization

Mon, 20 Oct 2025 09:05:29 -0400

Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced a joint commercialization agreement with RedHill Biopharma Ltd. (NASDAQ: RDHL) for Talicia, an FDA-approved treatment for Helicobacter pylori infection in adults.
Under the agreement, the companies will form a jointly owned entity. RedHill will contribute Talicia assets, including international licenses and associated revenues, while Cumberland will provide $4 million in investment capital. Cumberland will handle distribution and record product sales, with both companies sharing net revenues equally.
Talicia generated $8 million in net revenues in 2024. The oral capsule combines omeprazole, amoxicillin and rifabutin in a single treatment and demonstrates eradication rates above 90%. The American

Cumberland Pharmaceuticals partners with RedHill for Talicia commercialization

Mon, 20 Oct 2025 09:05:29 -0400

Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced a joint commercialization agreement with RedHill Biopharma Ltd. (NASDAQ: RDHL) for Talicia, an FDA-approved treatment for Helicobacter pylori infection in adults.
Under the agreement, the companies will form a jointly owned entity. RedHill will contribute Talicia assets, including international licenses and associated revenues, while Cumberland will provide $4 million in investment capital. Cumberland will handle distribution and record product sales, with both companies sharing net revenues equally.
Talicia generated $8 million in net revenues in 2024. The oral capsule combines omeprazole, amoxicillin and rifabutin in a single treatment and demonstrates eradication rates above 90%. The American

CUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO

Mon, 20 Oct 2025 09:05:00 -0400

Cumberland to expand its gastroenterology offerings with the market-leading Helicobacter pylori therapy

CUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO

Mon, 20 Oct 2025 09:05:00 -0400

Cumberland to expand its gastroenterology offerings with the market-leading Helicobacter pylori therapy

CUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO

Mon, 20 Oct 2025 09:05:00 -0400

Cumberland to expand its gastroenterology offerings with the market-leading Helicobacter pylori therapy

CUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO

Mon, 20 Oct 2025 09:05:00 -0400

Cumberland to expand its gastroenterology offerings with the market-leading Helicobacter pylori therapy

CUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO

Mon, 20 Oct 2025 09:05:00 -0400

Cumberland to expand its gastroenterology offerings with the market-leading Helicobacter pylori therapy

CUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO

Mon, 20 Oct 2025 09:05:00 -0400

Cumberland to expand its gastroenterology offerings with the market-leading Helicobacter pylori therapy

CUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO

Mon, 20 Oct 2025 09:05:00 -0400

Cumberland to expand its gastroenterology offerings with the market-leading Helicobacter pylori therapy